Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

athenahealth_More Disruption Please Conf 2016

athenahealth: More Disruption Please Conference 2016

athenahealth: More Disruption Please Conference 2016

Summary

Related Content

FDA Accepts Dr. Reddy’s Laboratories’ BLA for Abatacept Biosimilar

Janssen Files BPCIA Complaint Against Bio-Thera and Accord Related to Golimumab Biosimilar

2025 Year in Review: Life Sciences Licensing & Collaboration Deals

Genentech Brings Pertuzumab Biosimilar Fight to the ITC

European Biosimilar Updates

US Senate Probes FDA Bureaucracy vs. Innovation

Stronger Together: NORD’s Congressional Briefing on the Heels of FDA’s “Plausible Mechanism” Draft Guidance

FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN

Goodwin Advises Korro on Oversubscribed $85 Million Private Placement

Goodwin Represents Teva on $400 Million Strategic Growth Capital Agreement With Blackstone Life Sciences to Advance duvakitug

Goodwin Advises Bicara Therapeutics on Closing of $172.5 Million Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advises Generate Biomedicines, Inc. on the Closing of its $400 Million Initial Public Offering

Goodwin Represents Harbour BioMed on License Agreement and Equity Partnership for a Clinical-Stage Antibody for $105 Million Upfront and Up to $1.1 Billion in Milestones

Alven Invests in the €32 Million Series A Financing of Verley

Life Sciences Group of the Year: Goodwin (Law360)

Goodwin Guides Candel Therapeutics on $100 Million Public Offering and $100 Millon Royalty Funding Agreement With RTW

Life Sciences